A


B

ventral view

ventral dorsal


Supplementary Figure 1. In vivo imaging of mammary glands with Isovue-300 in 70\% ethanolcontaining solution. A) lodine-based contrast agent-containing solution of $70 \% \mathrm{EtOH}$ was sequentially injected within 15 min in left abdominal (\#4), left thoracic (\#2), and right abdominal gland (\#9); full-body microCT scan was acquired immediately after the last ID injection. B) Sequential 4 min . high-resolution microCT scans were acquired from independent animals whose abdominal glands were injected with iodinebased contrast agent-containing solution of PBS or $70 \% \mathrm{EtOH}$. Different angle views and time points of the same representative glands are shown. Voxels with signal intensities from -500 to 500 Hounsfield units in original CT slices were selected for volume rendition of diffused contrast agent. Scale bars indicate 1 mm in image panels at different magnification.
 transmission electron microscopy (TEM). TEM image show excellent homogeneity in size and morphology of $\mathrm{TaO}_{x}$ NCs. TEM images were acquired on a 2200FS JEOL electron microscope. These $\mathrm{TaO}_{x}$ NCs were prepared as follows: In a 250 mL , one neck round bottom flask, fitted with a septa, IGEPAL®-CO520 (average $M_{n} 441$, ALDRICH, 23.0 g ), Cyclohexane ( $\geq 99 \%$, A.C.S. spectrophotometric grade, SIGMAALDRICH, 200 mL ) and Ethanol ( 200 Proof, Anhydrous, KOPTEC USP, 2.5 mL ), were added and the contents were stirred to obtain a clear solution. To this stirring mixture, a solution of Sodium Hydroxide (100 $\mathrm{mM}, 2.5 \mathrm{~mL}$ ) was added and the micro-emulsion was sonicated in a water bath to ensure homogeneity. Next, Tantalum (V) ethoxide, ( $\mathrm{Ta}_{2} \mathrm{O}_{5}, 99.98 \%$ trace metal basis, $\mathrm{ALDRICH}, 0.5 \mathrm{~mL}$ ) was added in one portion and the contents were stirred at ambient temperature for 20 minutes. To the micro-emulsion mixture containing uncoated TaOx NCs, 2-[Methoxy (polyethyleneoxy)-9-12-propyl]trimethoxysilane (PEG-Silane, tech-90, MW 591-723, GELEST INC., 3.0 mL ), quickly followed by (3-Aminopropyl)trimethoxysilane (APTMS, 97\%, ALDRICH, $\quad 0.028 \mathrm{~mL}$ ) were added. The resulting milky white suspension solution was stirred at room temperature for 16 h . After 16 h , the reaction mixture was diluted to three times volume using a $1: 1$ mixture of Ethyl Ether (Anhydrous, Certified ACS, Fisher Scientific, 110 mL ) and Hexane (meets ACS specifications, VWR Chemicals, 110 mL ) and the NCs were isolated via centrifugation ( $15,000 \mathrm{rpm}, 10$ minutes, $10^{\circ} \mathrm{C}$ ) as white oily residue. This residue was suspended in ethyl ether and washed using a similar centrifugation procedure twice. The supernatants were discarded and the residue pellet so obtained was suspended in 100 mL Ethanol and Methoxy-poly(ethylene-glycol)-succinimidyl glutarate (m-PEG-SG-2000, Average MW 2000, LAYSAN BIO INC., 50 mg ) was added to it. The contents so obtained were stirred at room temperature in the dark for 12 h . Then, the solvent was removed on a rotary evaporator to reduce the volume to about 5 mL . This final residual solution was dissolved in water ( 10 mL ) and transferred to Dialysis Membrane bags (SPECTRA/POR® 6 Dialysis Membrane, Standard RC Tubing, MWCO: 1 kD), clipped at both ends and dialyzed against water with regular change of external media after 2, 4, 16, 4, 4 and 16 h . After extensive dialysis, the contents in the dialysis bags were lyophilized to obtain the $\mathrm{TaO}_{\times} \mathrm{NCs}$ as a white fluffy powder. Product Yield: 940 mg . Ta\% = 30\% (calculated from ICP-OES).

|  |  | Size (d.nm): | \% Number | Width (d.nm... |  |
| ---: | :--- | :--- | :--- | :--- | :--- |
| Z-Average (d.nm): | 43.05 | Peak 1: | 9.036 | 100.0 | 2.616 |
| Pdl: | 0.458 | Peak 2: | 0.000 | 0.0 | 0.000 |
| Intercept: | 0.758 | Peak 3: | 0.000 | 0.0 | 0.000 |

Result quality : Good


Supplementary Figure 3. Characterization of $\mathrm{TaO}_{\mathrm{x}}$ nanocrystals by Dynamic Light Scattering (DLS). DLS plot shows a narrow range of particle size distribution. $\mathrm{TaO}_{x}$ were analyzed in hydrophilic conditions by dissolving TaOx nanocrystals at $1 \mathrm{mg} / \mathrm{mL}$ in water. DLS plot was acquired on a Zetasizer instrument (Malvern, USA).

|  |  | Tumor in non-injected gland |  |  |  |  |  |  |  |  |  | Tumor in injected gland |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ID | experimental group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 90 | untreated | N | N | N | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 101 | untreated | Y | Y | N | N | N | Y | N | Y | Y | Y |  |  |  |  |  |  |  |  |  |  |
| 106 | untreated | Y | Y | N | N | N | N | N | Y | N | Y |  |  |  |  |  |  |  |  |  |  |
| 108 | untreated | Y | Y | N | Y | Y | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 109 | untreated | Y | N | Y | N | N | N | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 112 | untreated | Y | N | N | N | N | Y | N | Y | N | N |  |  |  |  |  |  |  |  |  |  |
| 115 | untreated | N | Y | N | Y | N | N | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 121 | untreated | N | Y | Y | N | N | Y | N | N | Y | N |  |  |  |  |  |  |  |  |  |  |
| 124 | untreated | Y | Y | Y | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 137 | untreated | Y | N | Y | N | N | N | Y | Y | Y | N |  |  |  |  |  |  |  |  |  |  |
| 155 | untreated | Y | N | N | Y | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 156 | untreated | Y | Y | N | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 158 | untreated | N | Y | N | Y | Y | Y | N | N | Y | Y |  |  |  |  |  |  |  |  |  |  |
| 161 | untreated | N | N | N | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 167 | untreated | N | N | Y | Y | Y | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 170 | untreated | N | N | N | Y | Y | N | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 175 | untreated | Y | N | N | N | N | Y | Y | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 192 | untreated | Y | N | N | N | N | Y | N | Y | Y | N |  |  |  |  |  |  |  |  |  |  |
| 196 | untreated | N | N | Y | N | N | N | N | N | Y | N |  |  |  |  |  |  |  |  |  |  |
| 202 | untreated | Y | N | N | Y | N | Y | N | Y | Y | N |  |  |  |  |  |  |  |  |  |  |
| 203 | untreated | Y | N | N | N | N | Y | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 208 | untreated | N | N | N | N | N | N | Y | Y | N | N |  |  |  |  |  |  |  |  |  |  |
| 213 | untreated | N | Y | Y | N | N | Y | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 218 | untreated | Y | N | N | Y | N | Y | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 219 | untreated | N | N | N | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 311 | carprofen only | N | Y | N | N | Y | N | Y | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 312 | carprofen only | Y | N | N | N | N | N | Y | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 314 | carprofen only | N | N | N | N | N | N | Y | Y | N | N |  |  |  |  |  |  |  |  |  |  |
| 315 | carprofen only | Y | N | N | N | N | Y | N | N | Y | Y |  |  |  |  |  |  |  |  |  |  |
| 318 | carprofen only | N | N | N | Y | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 319 | carprofen only | Y | N | N | N | N | Y | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 322 | carprofen only | Y | N | N | N | N | Y | N | N | N | Y |  |  |  |  |  |  |  |  |  |  |
| 323 | carprofen only | Y | Y | N | N | N | N | Y | N | Y | N |  |  |  |  |  |  |  |  |  |  |
| 325 | carprofen only | Y | N | N | N | N | Y | N | N | N | N |  |  |  |  |  |  |  |  |  |  |
| 327 | carprofen only | Y | N | N | N | N | N | Y | N | N | N |  |  |  |  |  |  |  |  |  |  |


| 207 | PBS | Y |  |  |  |  | Y |  |  | Y |  |  | Y | N | Y | N |  | Y | N |  | N |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 209 | PBS |  |  |  |  | N | N |  |  |  | N | Y | Y | N | N |  |  | N | N | N |  |
| 215 | PBS |  | Y |  | Y | N |  |  |  |  | N | Y |  |  | N |  | Y | Y | N | N |  |
| 216 | PBS | Y |  |  |  |  | Y |  |  |  | N |  | Y | N | Y | N |  | Y | Y | N |  |
| 220 | PBS |  |  | Y |  | Y | N | N |  |  | N | Y | Y |  | Y |  |  |  | N | N |  |
| 222 | PBS |  |  | Y |  |  | N |  | N |  | N | Y | N |  | N | N |  | N |  | N |  |
| 231 | PBS | Y |  | N |  |  | N | Y |  | Y |  |  | Y |  | Y | N |  |  | Y |  | Y |
| 241 | PBS | Y |  | Y |  |  | Y | Y |  | Y |  |  | Y |  | Y | Y |  |  | N |  | Y |


| 242 | PBS | Y | Y | Y |  | Y | Y |  | Y |  | Y | Y |  | Y | N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 243 | PBS | $Y$ | N |  | N | Y | N | N | Y | N |  | N | Y |  |  |


| 280 | $50 \%$ EtOH[Contrast/PBS] | N | Y | Y |  |  | N |  |  |  | N |  |  |  | N | N |  | Y | N | N |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 285 | $50 \%$ EtOH[Contrast/PBS] | Y | N | Y | N | Y | N | Y | N |  |  |  |  |  |  |  |  |  |  | N | N |
| 286 | $50 \%$ EtOH[Contrast/PBS] | Y | N | N |  |  | Y |  |  | N | N |  |  |  | N | N |  | N | N |  |  |
| 287 | $50 \%$ EtOH[Contrast/PBS] | Y | N | N |  | N | N |  |  |  | N |  |  |  | N |  |  | N | N | Y |  |
| 288 | $50 \%$ EtOH[Contrast/PBS] | Y | N |  |  | Y | Y |  |  |  |  |  |  | N | N |  |  | Y | N | Y | N |
| 290 | $50 \%$ EtOH[Contrast/PBS] | N | N |  | N | Y | N | N |  |  | N |  |  | N |  |  |  |  | N | N |  |


| 297 | 70\% EtOH[Contrast/PBS] | Y | Y |  | Y |  | N |  |  |  | N |  |  | N |  | N | Y | Y | N |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 304 | 70\% EtOH[Contrast/PBS] | N | N | N |  | N | N |  | Y |  | N |  |  |  | N |  | N |  | N |  |
| 305 | 70\% EtOH[Contrast/PBS] | Y |  |  |  | Y | N |  | Y |  | N |  | N | N | N |  | N |  | N |  |
| 308 | 70\% EtOH[Contrast/PBS] | Y | N | N |  | N | Y |  |  | N | N |  |  |  | N |  | N | N |  |  |
| 309 | 70\% EtOH[Contrast/PBS] | N | Y |  |  |  | N |  | Y | N |  |  |  | N | N | N | N |  |  | N |
| 316 | 70\% EtOH[Contrast/PBS] |  | Y |  |  | N | Y | N |  |  | N | N |  | N | N |  |  | N | N |  |
| 317 | 70\% EtOH[Contrast/PBS] | Y |  |  | N | Y | $Y$ |  | Y |  | Y |  | N | N |  |  | N |  | N |  |
| 324 | 70\% EtOH[Contrast/PBS] | Y |  |  | Y | N | Y |  |  |  | N |  | N | Y |  |  | N | N | N |  |
| 338 | 70\% EtOH[Contrast/PBS] |  |  | Y |  |  | $Y$ |  |  |  | N | Y | N | N | N |  | N | N | N |  |
| 341 | 70\% EtOH[Contrast/PBS] | Y |  |  |  |  | N |  | Y |  | N |  | N | N | N | N | N |  | N |  |
| 342 | 70\% EtOH[Contrast/PBS] | $Y$ |  | Y |  | N | Y |  | Y |  | Y |  | Y |  | N |  | N |  | N |  |


| 188 | 70\% EtOH[H2O] | Y | N | N |  |  |  |  |  | N | N |  |  |  | N | N | N | N | N |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 190 | 70\% EtOH[H2O] | Y |  |  |  |  | N | N | N |  |  |  | N | N | N | N |  |  |  | N | N |
| 193 | 70\% EtOH[H2O] |  |  |  |  | N | Y | Y | N |  |  | N | N | N | N |  |  |  |  | N | N |
| 200 | 70\% EtOH[H2O] | N | Y | N |  |  | N | N | N |  |  |  |  |  | N | N |  |  |  | N | N |
| 291 | 70\% EtOH[H2O] |  | Y |  |  |  |  |  |  |  |  | N |  | N | N | Y | N | N | N | N | N |
| 292 | 70\% EtOH[H2O] | Y |  |  |  |  |  | Y | N | Y |  |  | N | N | N | N | N |  |  |  | N |
| 294 | 70\% EtOH[H2O] |  |  | Y |  |  |  |  |  |  |  | N | N |  | N | N | N | N | N | N | N |
| 296 | 70\% EtOH[H2O] |  |  |  |  |  |  | Y |  |  |  | N | N | N | N | N | N |  | N | N | N |
| 299 | 70\% EtOH[H2O] |  | Y |  |  |  |  |  |  |  |  | N |  | N | N | N | Y | N | N | N | N |
| 300 | 70\% EtOH[H2O] | Y |  |  | Y |  | Y |  |  |  |  |  | N | N |  | Y |  | N | N | N | N |
| 301 | 70\% EtOH[H2O] |  | Y |  |  |  |  |  | Y |  |  | N |  | N | N | N | Y | Y |  | N | N |
| 307 | 70\% EtOH[H2O] |  |  |  | Y |  |  |  |  |  |  | Y | N | N |  | N | N | N | N | N | N |
| 310 | 70\% EtOH[H2O] |  |  |  |  | Y |  | Y |  |  |  | N | N | N | N |  | Y |  | N | N | N |

Supplementary Table 1. Tumor formation in non-injected and injected mammary glands assessed at necropsy. Presence of a tumor at necropsy is indicated with a " $Y$ " for yes and absence with a " $N$ " for no. Fields are left blank for mammary glands that were not part of that experimental group or class. Mammary gland location code: 1 = left cervical; 2 = left upper thoracic; $3=$ left lower thoracic; $4=$ left abdominal; $5=$ left inguinal; $6=$ right cervical; $7=$ right upper thoracic; $8=$ right lower thoracic; $9=$ right abdominal; $10=$ right inguinal.

